FDA records linked by MedtechLedger list Merz North America, Inc. at 6501 Six Forks Road, Raleigh, NC, as the applicant on two premarket approvals and three supplements for Belotero-branded dermal fillers. The filings cover original approvals for cheek augmentation and lip augmentation indications and later manufacturing and labeling changes. The records establish the applicant identity and the regulatory scope of each submission; they do not establish corporate ownership, headquarters, commercial availability or clinical performance. [1][4][5][8][10]
Two approved dermal filler PMAs
P250020 covers Belotero Volume (+) Lidocaine Dermal Filler, approved May 19, 2026, for deep subcutaneous and/or supraperiosteal injection to improve volume deficit in the mid-face or correct mid-face contour deficiencies in adults 22 years or older. P250016 covers Belotero Intense (+) Lidocaine, approved July 9, 2026, for submucosal and/or subcutaneous implantation for lip augmentation in adults over 21. Both are class III devices under product code LMH, generic name implant, dermal, for aesthetic use. [4][5][8][10]
Supplements and their scope
Three supplements appear in the record sample. P250020/S004, a normal 180-day track labeling change, was approved November 4, 2026, for a change to release and shelf-life specifications for Belotero Volume (+) Lidocaine. P250016/S006, a 30-day notice received September 23, 2026 and decided October 21, 2026, covers modifications to the manual cleaning process for utensils and equipment used in manufacturing Belotero Intense (+) Lidocaine. P250020/S005, a 30-day notice decided September 10, 2026, covers requalification of cleanroom and controlled manufacturing areas at the Merz Aesthetics GmbH facility identified by FEI 3036164410. [1][2][3]
What the published documentation describes
The manufacturer’s prescribing information for Belotero Volume (+) Lidocaine includes a pivotal study of the product for cheek augmentation. The FDA summary of safety and effectiveness data for P250020 records an approval order dated May 19, 2026 and describes an inspection of the applicant’s manufacturing facilities. The P250016 summary also discusses the manufacturing inspection and refers readers to device labeling for hazards, contraindications, warnings and adverse events. These statements describe the cited FDA documents and their recorded scope. [6][8][10]
Reading the filing counts
The collection holds five linked PMA records as of November 20, 2026: three approvals and two 30-day notices. The smaller record sample of five entries shows the same three-to-two split. These are counts of filings in the collection, not measures of total portfolio size, sales or safety performance. The record sample contains no recall entries. [1][2][3][4][5]








